DJ Roche Huntington-Disease Trial Halt Seen as Setback to Sentiment -- Market Talk
0849 GMT - The halt to Roche's phase-3 trial of Huntington-disease drug tominersen is presumably because the drug has insufficient efficacy, Jefferies says. Given the fact that tominersen was widely wiewed to be a significant blockbuster option in the Swiss major's pipeline, this news is a setback to sentiment, according to Jefferies. The drug had potential as a blockbuster asset, considering that no therapies are currently approved to slow the progression of the disease, Jefferies says.The investment bank reiterates its hold recommendation on Roche's stock. Roche trades down 1.8% at CHF309.35. (cecilia.butini@wsj.com)
(END) Dow Jones Newswires
March 23, 2021 04:49 ET (08:49 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.